BioVersys AG successfully closes Series A2 financing round

November 20, 2017
BioVersys AG

BioVersys AG announced today that it has successfully closed a Series A2 financing round of CHF 5 million with existing private investors. “We would like to thank our investors for their ongoing support. The funds will be used to prepare for clinical development with BioVersys’ lead project directed at Tuberculosis and to advance our discovery pipeline directed against antimicrobial resistance” commented Dr. Marc Gitzinger (CEO). 

Download the press release.